{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:53:34Z","timestamp":1790679214740,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T00:00:00Z","timestamp":1516147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","seminarsinnephrology.org","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.semnephrol.2018.01.007","type":"journal-article","created":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T22:13:45Z","timestamp":1522188825000},"page":"183-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Targeting Glucosylceramide Synthesis in the Treatment of Rare and Common Renal Disease"],"prefix":"10.1016","volume":"38","author":[{"given":"James A.","family":"Shayman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2018.01.007_bib1","series-title":"A Treatise on the Chemical Constitution of Brain","author":"Thudichum","year":"1884"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1146\/annurev.ph.28.030166.002251","article-title":"Functions of lysosomes","volume":"28","author":"De Duve","year":"1966","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib3","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nrm1423","article-title":"The cell biology of lysosomal storage disorders","volume":"5","author":"Futerman","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib4","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1021\/cr2002917","article-title":"Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics","volume":"111","author":"Merrill","year":"2011","journal-title":"Chem Rev"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib5","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0021-9258(19)42911-6","article-title":"The enzymatic formation of sphingomyelin from ceramide and lecithin in mouse liver","volume":"249","author":"Ullman","year":"1974","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib6","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0021-9258(19)44311-1","article-title":"Enzymatic synthesis of glucocerebroside by a glucosyltransferase from embryonic chicken brain","volume":"248","author":"Basu","year":"1973","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib7","doi-asserted-by":"crossref","unstructured":"Morell P, Radin NS. Synthesis of cerebroside by brain from uridine diphosphate galactose and ceramide containing hydroxy fatty acid. Biochemistry. 19698:506-512.","DOI":"10.1021\/bi00830a008"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib8","first-page":"F291","article-title":"Structure and function of renal glycosphingolipids","volume":"260","author":"Shayman","year":"1991","journal-title":"Am J Physiol"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib9","doi-asserted-by":"crossref","first-page":"25859","DOI":"10.1074\/jbc.R200001200","article-title":"Combinatorial ganglioside biosynthesis","volume":"277","author":"Kolter","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1600-0854.2004.00176.x","article-title":"Invisible rafts at work","volume":"5","author":"van Meer","year":"2004","journal-title":"Traffic"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib11","first-page":"197","article-title":"Methods for the identification of host receptors for Shiga toxin","volume":"73","author":"Nutikka","year":"2003","journal-title":"Methods Mol Med"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib12","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N Engl J Med"},{"issue":"Suppl:","key":"10.1016\/j.semnephrol.2018.01.007_bib13","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1194\/jlr.R800080-JLR200","article-title":"Bioactive sphingolipids: metabolism and function","volume":"50","author":"Bartke","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nchembio.392","article-title":"An update on sphingosine-1-phosphate and other sphingolipid mediators","volume":"6","author":"Fyrst","year":"2010","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib15","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1021\/cr200273u","article-title":"Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors","volume":"111","author":"Blaho","year":"2011","journal-title":"Chem Rev"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib16","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1172\/JCI89626","article-title":"Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency","volume":"127","author":"Lovric","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib17","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1083\/jcb.117.2.259","article-title":"Glucosylceramide is synthesized at the cytosolic surface of various Golgi subfractions","volume":"117","author":"Jeckel","year":"1992","journal-title":"J Cell Biol"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib18","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib19","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1172\/JCI116299","article-title":"A role for glycosphingolipid accumulation in the renal hypertrophy of streptozotocin-induced diabetes-mellitus","volume":"91","author":"Zador","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib20","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/S0022-2275(20)41159-9","article-title":"Abnormalities of glycosphingolipid, sulfatide, and ceramide in the polycystic (Cpk\/Cpk) mouse","volume":"35","author":"Deshmukh","year":"1994","journal-title":"J Lipid Res"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib21","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.1174447","article-title":"A gene network regulating lysosomal biogenesis and function","volume":"325","author":"Sardiello","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib22","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1242\/jcs.146365","article-title":"TFEB at a glance","volume":"129","author":"Napolitano","year":"2016","journal-title":"J Cell Sci"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF00731489","article-title":"Treatment of Gaucher disease with an enzyme inhibitor","volume":"13","author":"Radin","year":"1996","journal-title":"Glycoconj J"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0076-6879(00)11097-3","article-title":"Inhibitors of glucosylceramide synthase","volume":"311","author":"Shayman","year":"2000","journal-title":"Sphingolipid Metab Cell Signal Pt A"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/oxfordjournals.jbchem.a123736","article-title":"Improved inhibitors of glucosylceramide synthase","volume":"111","author":"Abe","year":"1992","journal-title":"J Biochem"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib26","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1016\/S0040-4039(00)76999-1","article-title":"Studies on morpholinosphingolipids - potent inhibitors of glucosylceramide synthase","volume":"35","author":"Carson","year":"1994","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib27","doi-asserted-by":"crossref","first-page":"14662","DOI":"10.1074\/jbc.274.21.14662","article-title":"Improved inhibitors of glucosylceramide synthase","volume":"274","author":"Lee","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib28","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1172\/JCI9711","article-title":"Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation","volume":"105","author":"Abe","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10545-010-9072-z","article-title":"Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy","volume":"33","author":"Marshall","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib30","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1358\/dof.2010.035.08.1505566","article-title":"Eliglustat Tartrate: Glucosylceramide synthase inhibitor treatment of type 1 Gaucher disease","volume":"35","author":"Shayman","year":"2010","journal-title":"Drugs Future"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib31","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","article-title":"Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial","volume":"385","author":"Cox","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib32","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jama.2015.459","article-title":"Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial","volume":"313","author":"Mistry","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib33","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2147\/TCRM.S6865","article-title":"Review of miglustat for clinical management in Gaucher disease type 1","volume":"4","author":"Ficicioglu","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib34","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1021\/mp200313e","article-title":"Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase","volume":"8","author":"Abian","year":"2011","journal-title":"Mol Pharm"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib35","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","article-title":"Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry","volume":"30","author":"Eng","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib36","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/01.ASN.0000043901.45141.D4","article-title":"Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis","volume":"14","author":"Eitzman","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib37","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1161\/01.CIR.0000154550.15963.80","article-title":"alpha-Galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency","volume":"111","author":"Bodary","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib38","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1440-1681.2008.04984.x","article-title":"Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect","volume":"35","author":"Park","year":"2008","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib39","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1681\/ASN.2005040383","article-title":"An in vitro model of Fabry disease","volume":"16","author":"Shu","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib40","doi-asserted-by":"crossref","first-page":"20960","DOI":"10.1074\/jbc.M702436200","article-title":"Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of alpha-galactosidase A null mice","volume":"282","author":"Shu","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib41","first-page":"1","article-title":"Glycosphingolipid mediated caveolin-1 oligomerization","volume":"S2","author":"Shu","year":"2012","journal-title":"J Glycomics Lipidomics"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib42","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0891-5849(02)00792-X","article-title":"Oxidized amino acids: culprits in human atherosclerosis and indicators of oxidative stress","volume":"32","author":"Heinecke","year":"2002","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib43","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/ki.2013.520","article-title":"Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease","volume":"86","author":"Shu","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib44","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib45","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/jcph.944","article-title":"Lucerastat, an iminosugar for substrate reduction therapy: pharmacokinetics, tolerability, and safety in subjects with mild, moderate, and severe renal function impairment","volume":"57","author":"Guerard","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib46","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/mt.2016.53","article-title":"CNS-accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic Gaucher disease","volume":"24","author":"Marshall","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib47","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/hep.23175","article-title":"Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice","volume":"50","author":"Bijl","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib48","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.cmet.2012.04.002","article-title":"A ceramide-centric view of insulin resistance","volume":"15","author":"Chavez","year":"2012","journal-title":"Cell Metab"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib49","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1074\/jbc.M103705200","article-title":"Ganglioside GM3 participates in the pathological conditions of insulin resistance","volume":"277","author":"Tagami","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib50","doi-asserted-by":"crossref","first-page":"13678","DOI":"10.1073\/pnas.0703650104","article-title":"Dissociation of the insulin receptor and caveolin-1 complex by ganglioside GM3 in the state of insulin resistance","volume":"104","author":"Kabayama","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib51","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1073\/pnas.0635898100","article-title":"Enhanced insulin sensitivity in mice lacking ganglioside GM3","volume":"100","author":"Yamashita","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib52","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hep.22970","article-title":"Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice","volume":"50","author":"Zhao","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib53","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2337\/db06-1619","article-title":"Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity","volume":"56","author":"Aerts","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.plipres.2010.10.006","article-title":"Group XV phospholipase A, a lysosomal phospholipase A","volume":"50","author":"Shayman","year":"2011","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib55","doi-asserted-by":"crossref","first-page":"F204","DOI":"10.1152\/ajprenal.00150.2015","article-title":"Kidney glycosphingolipids are elevated early in diabetic nephropathy and mediate hypertrophy of mesangial cells","volume":"309","author":"Subathra","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib56","doi-asserted-by":"crossref","first-page":"40419","DOI":"10.1074\/jbc.M405079200","article-title":"Calcium restriction allows cAMP activation of the B-Raf\/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype","volume":"279","author":"Yamaguchi","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib57","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/ng1552","article-title":"Inversin, the gene product mutated in nephronophthisis type II, functions as a molecular switch between Wnt signaling pathways","volume":"37","author":"Simons","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib58","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1083\/jcb.200503053","article-title":"Cilia and the cell cycle?","volume":"169","author":"Quarmby","year":"2005","journal-title":"J Cell Biol"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib59","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nm.2171","article-title":"Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models","volume":"16","author":"Natoli","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib60","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1093\/hmg\/dds172","article-title":"Loss of GM3 synthase gene, but not sphingosine kinase 1, is protective against murine nephronophthisis-related polycystic kidney disease","volume":"21","author":"Natoli","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.semnephrol.2018.01.007_bib61","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1172\/JCI11194","article-title":"A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease","volume":"107","author":"Pennathur","year":"2001","journal-title":"J Clin Invest"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027092951830007X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027092951830007X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T04:11:28Z","timestamp":1660709488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027092951830007X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S027092951830007X"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2018.01.007","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting Glucosylceramide Synthesis in the Treatment of Rare and Common Renal Disease","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2018.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}